RecruitingSolid TumorAdvanced Solid Tumor
A Study of PYX-201 in Advanced Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
14 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Sponsor: Pyxis Oncology, Inc
Where it's recruiting
Arizona
Scottsdale
California
Los Angeles
Colorado
Denver
Florida
Sarasota
Georgia
Atlanta
Illinois
Chicago
Massachusetts
Boston
Missouri
St Louis
New York
New York
Ohio
Cincinnati
Pennsylvania
Philadelphia
Rhode Island
Providence
Source: ClinicalTrials.gov · NCT05720117 · last updated 2026-06-30